Interview with Chen Chun Lin, Co-Chairman, Medicilon/MPI Preclinical Research…
You completed your higher education in the US and worked there for a period afterwards; what caused you to move back to China and start this company? A lot of…
Address: 585 Chuanda Road, Pudong New AreaShanghai, 201200,China
Tel: +86 21 31268381
Web: http://www.medicilon-mpi.com/
As a newly formed joint venture located in China, Medicilon/MPI Preclinical Research Shanghai provides a portfolio of preclinical discovery and development services to pharmaceutical and biotechnology companies.
Medicilon/MPI Preclinical Research Shanghai has brought together the best of its parent companies, Shanghai Medicilon and MPI Research, to assure top quality, on-time GLP and non-GLP studies.
toxicology services
You completed your higher education in the US and worked there for a period afterwards; what caused you to move back to China and start this company? A lot of…
Perhaps Chinese biotech’s biggest success story, cancer-focused Beigene has evolved from the commitment of founders John Oyler and Xiaodong Wang to conducting clinical research in China with a global outlook.…
Portuguese national Isabel Afonso, a Novartis and Sandoz veteran of almost 20 years, has taken on a new role as general manager of Novartis’ highly strategic oncology franchise in China…
The latest news from Chinese pharma, including a new report showing that despite the increasing number of Priority Review and Breakthrough Therapy designations awarded within China, only two Accelerated Approval…
The latest news from Chinese pharma and biotech, including BMS’ attempts to pull out of its Abraxane supply deal with local player BeiGene; a conversation with Qihan Biotech CEO Luhan…
The following is an overview from Accestra Consulting* of Part 2 of China’s Center for Drug Evaluation (CDE)’s 2020 reporting, including an overview of administrative drug approvals and fast track…
The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its own mRNA vaccine; an update on Hong Kong’s biotech investment ecosystem three year…
Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), picks out the key learnings from recent legislation to improve China’s drug regulatory capacity and why it…
The following is an overview from Accestra Consulting* of Part 1 of China’s Center for Drug Evaluation (CDE)’s 2020 reporting, including data on drug approvals for all application types (including…
The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli Lilly, Merck & Co., Novartis, Novo Nordisk, and Sanofi have achieved China growth in…
In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric Bouteiller examine the potential impact of China’s revision to its patent law on the…
In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong Chow has left her role as General Manager for Roche…
The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant Simcere and German biotech Vivoryon in Alzheimer’s; Innovent’s tie-up with Ascentage; Biogen’s USD 125 million…
See our Cookie Privacy Policy Here
